Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,430
datasets available to search
ShareScore release 0.9.0
Dataset results
3,430 results for “PD”
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
ClinicalTrials.gov study NCT03708328. IPD Sharing: NO. Countries: 6. Publications: 0.
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastat
ClinicalTrials.gov study NCT04199104. IPD Sharing: YES. Countries: 19. Publications: 1.
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NS
ClinicalTrials.gov study NCT03625323. IPD Sharing: NO. Countries: 1. Publications: 1.
A comparative study on the stability of the furfural molecule on the low index Ni, Pd and Pt surfaces
Open the record for dataset details and reuse information.
Metabolomic analysis of cultured TRAMP-C2 cells in the presence or absence of PD-L1 expression
Open the record for dataset details and reuse information.
Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma
Open the record for dataset details and reuse information.
Acinetobacter lwoffii exposure promotes PD-L1+ neutrophils and dampens viral-induced type 2 immunity
Open the record for dataset details and reuse information.
Data from: Direct propylene epoxidation via water activation over Pd-Pt electrocatalysts
Open the record for dataset details and reuse information.
Pairwise distance demarcation of species in the family Coronaviridae. a, Diagonal matrix of PPDs of 2,505 viruses clustered according to 49 coronavirus species, 39 established and 10 pending or tentative, and ordered from the most to least populous species, from left to right; green and white, PPDs smaller and larger than the inter-species threshold, respectively. Areas of the green squares along the diagonal are proportional to the virus sampling of the respective species, and virus prototypes of the five most sampled species are specified to the left; asterisks indicate species that include viruses whose intra-species PPDs crossed the inter-species threshold (threshold 'violators'). b, Maximal intra-species PPDs (x axis, linear scale) plotted against virus sampling (y axis, log scale) for 49 species (green dots) of the Coronaviridae. Indicated are the acronyms of virus prototypes of the seven most sampled species. Green and blue plot sections represent intra-species and intra-subgenera PPD ranges. The vertical black line indicates the inter-species threshold. c, Shown are the PDs of non-identical residues (y axis) for four viruses representing three major phylogenetic lineages (clades) of the species Severe acute respiratorysyndrome-related coronavirus (panel b) and all pairs of the 256 viruses of this species ('all pairs'). The PD values were derived from pairwise distances in the MSA that were calculated using an identity matrix. Panels a and b were adopted from the DEmARC v.1.4 output. in The species Severe acute respiratory syndromerelated coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
Pairwise distance demarcation of species in the family Coronaviridae. a, Diagonal matrix of PPDs of 2,505 viruses clustered according to 49 coronavirus species, 39 established and 10 pending or tentative, and ordered from the most to least populous species, from left to right; green and white, PPDs smaller and larger than the inter-species threshold, respectively. Areas of the green squares along the diagonal are proportional to the virus sampling of the respective species, and virus prototypes of the five most sampled species are specified to the left; asterisks indicate species that include viruses whose intra-species PPDs crossed the inter-species threshold (threshold 'violators'). b, Maximal intra-species PPDs (x axis, linear scale) plotted against virus sampling (y axis, log scale) for 49 species (green dots) of the Coronaviridae. Indicated are the acronyms of virus prototypes of the seven most sampled species. Green and blue plot sections represent intra-species and intra-subgenera PPD ranges. The vertical black line indicates the inter-species threshold. c, Shown are the PDs of non-identical residues (y axis) for four viruses representing three major phylogenetic lineages (clades) of the species Severe acute respiratorysyndrome-related coronavirus (panel b) and all pairs of the 256 viruses of this species ('all pairs'). The PD values were derived from pairwise distances in the MSA that were calculated using an identity matrix. Panels a and b were adopted from the DEmARC v.1.4 output.
Pd-based bimetallic catalysts in hydrogenation with parahydrogen
<p>Here is raw NMR data obtained while different Pd-based bimetallic catalysts were tested in gas-phase propyne hydrogenation with parahydrogen. </p> <p><strong>Folder PdAg Pd Ag:</strong></p> <p>1) spectra 1-13 - bimetallic Pd-Ag catalyst was tested at different gas flow rates at 100 C;</p> <p>2) spectra 14-21 - bimetallic Pd-Ag catalyst was tested at different gas flow rates at 200 C;</p> <p>3) spectra 22-29 - bimetallic Pd-Ag catalyst was tested at different gas flow rates at 300 C;</p> <p>4) spectra 30-32 - monometallic Ag catalyst was tested at different flow rates at 200 C;</p> <p>5) spectra 33-38 - monometallic Ag catalyst was tested at different flow rates at 300 C;</p> <p>6) spectra 39-47 - monometallic Pd catalyst was tested at different flow rates at 300 C;</p> <p>7) spectra 48-55 - monometallic Pd catalyst was tested at different flow rates at 200 C;</p> <p>8) spectra 56-63 - monometallic Pd catalyst was tested at different flow rates at 100 C;</p> <p>9) spectra 64-67 - monometallic Pd catalyst was tested at different flow rates at 50 C.</p> <p><strong>Folder PdIn:</strong></p> <p>1) spectra 300-308 - bimetallic PdIn catalyst was tested at different flow rates at 100 C;</p> <p>2) spectra 309-318 - bimetallic PdIn catalyst was tested at different flow rates at 200 C;</p> <p>3) spectra 319-326 - bimetallic PdIn catalyst was tested at different flow rates at 300 C;</p> <p>4) spectra 327-334 - bimetallic PdIn catalyst was tested at different flow rates at 400 C;</p> <p>5) spectra 335-342 - bimetallic PdIn catalyst was tested at different flow rates at 500 C;</p>
Genomic profiling of NSCLC tumors with the TruSight Oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1
<p>Wallen ZD, Ko H, Nesline MK, Tierno M, Roos A, Schnettler E, Husain H, Sathyan P, Caveney B, Eisenberg M, Severson EA, Ramkissoon SH. <strong>Genomic profiling of NSCLC tumors with the TruSight Oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic.</strong> <em>Front Oncol.</em> 2024 Nov 5;14:1473327. doi: <a href="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1473327">10.3389/fonc.2024.1473327</a>.</p> <p><strong>ABSTRACT</strong></p> <p><strong>Introduction: </strong>Matching patients to an effective targeted therapy or immunotherapy is a challenge for <br>advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one <br>marker at a time. Unlike traditional single marker tests, comprehensive genomic profiling (CGP) can <br>simultaneously assess NSCLC tumors for hundreds of genomic biomarkers and markers for immunotherapy <br>response, leading to quicker and more precise matches to therapeutics. <strong>Methods: </strong>In this study, we performed <br>CGP on 7,606 patients with advanced or metastatic NSCLC using the Illumina TruSight Oncology 500 (TSO <br>500) CGP assay to show its coverage and utility in detecting known and novel features of NSCLC. <strong>Results: </strong><br>Testing revealed distinct genomic profiles of lung adenocarcinoma and squamous cell carcinomas and <br>detected variants with a current targeted therapy or clinical trial in >72% of patient tumors. Known associations <br>between genomic alterations and immunotherapy markers were observed including significantly lower TMB <br>levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, <br>MET, BRAF, or ROS1 driver mutations. Co-occurrence analysis followed by network analysis with gene <br>module detection revealed known and novel co-occurrences between genomic alterations. Further, certain <br>modules of genes with co-occurring genomic alterations had dose-dependent relationships with histology and <br>increasing or decreasing levels of PD-L1 and TMB, suggesting a complex relationship between PD-L1, TMB, <br>and genomic alterations in these gene modules. <strong>Discussion:</strong> This study is the largest clinical study to date <br>utilizing the TSO 500. It provides an opportunity to further characterize the landscape of NSCLC using this <br>newer technology and show its clinical utility in detecting known and novel facets of NSCLC to inform treatment <br>decision-making.</p> <p><strong>DATA AVAILABILITY</strong></p> <p>The data and code presented in the study are deposited in this Zenodo repository, accession number <br>13137232 (<a href="https://zenodo.org/record/13137232">https://zenodo.org/record/13137232</a>). Raw sequencing data were derived from routine clinical testing of real-world patients and cannot be shared publicly. Further data inquiries can be directed to the corresponding <br>author. </p>
Distribution of lemma "digital" in PD and TE projects (2016, 2019, 2021)
<p>sdj</p>
Data and code for "Hydrogen-driven Surface Segregation in Pd-alloys from Atomic Scale Simulations"
<p>This record contains data and scripts pertaining to the publication "Hydrogen-driven Surface Segregation in Pd-alloys from Atomic Scale Simulations".</p>
CTLA-4 and PD-1 expressed in EMT6 mouse mammary carcinoma cell line acquired radio-resistance to gamma-ray irradiation.
<p>Supplementary File of manuscript entitled CTLA-4 and PD-1 expressed in EMT6 mouse mammary carcinoma cell line acquired radio-resistance to gamma-ray irradiation.</p>
Pd-exchanged BEA and CHA
<p>The data set contains:</p> <ul> <li>Nuclear repulsion energy: <ul> <li>xyz coordinates of CHA and BEA</li> <li>energies given in json file (CHA-NRE.json and BEA-NRE.jon)</li> </ul> </li> <li>Structures: <ul> <li>xyz coordinates of the DFT optimized structures of either Pd-exchanged zeolite (CHA or BEA) or proton compensating zeolite (also CHA and BEA)</li> <li>xyz coordinates are given for the full QM/MM atom and the QM atoms</li> </ul> </li> <li>energy.json: <ul> <li>the calculated DFT energy of the optimized structures</li> </ul> </li> <li>qm_region: <ul> <li>xyz coordinates of the optimized DFT structures at different number of atoms in the QM region</li> <li>data are given for both the full QM/MM atoms and the QM atoms</li> </ul> </li> <li>gas_traj: <ul> <li>xyz coordinates of the optimized DFT structures of various adsorbates on Pd-exchanged CHA</li> </ul> </li> </ul> <p>The nomenclature used to tabulate the data is as follow:</p> <ul> <li>zeolite name (CHA or BEA) - a number representing structure with a unique Al arrangement - adsorbate name (Pd+2, Pd+H+, Pd+, H+ or H+H+) - a number representing an initial position of the adsorbate - level of theory (GGA or hGGA) - type of calculations (opt for optimization and sp for single point calculation).</li> </ul>
Association of physical activity and APOE genotype with longitudinal cognitive change in early PD
<p><b>Objective:</b> To determine whether greater physical activity could modify the negative association of <i>APOE</i> <span>ε4 with longitudinal cognitive changes in early Parkinson's disease (PD) and to uncover the disease-specific mechanism for </span>explaining such benefits of physical activity<span>.</span></p> <p><b>Methods:</b> We used data from the Parkinson's Progression Markers Initiative cohort. Because self-reported physical activity, measured by the Physical Activity Scale of the Elderly, was initiated at 2 years after enrollment, this longitudinal analysis was based on assessments performed at years 2, 3, and 4. Cognitive function was measured annually with the Montreal Cognitive Assessment (MoCA). Dopamine transporter (DAT) imaging was performed at years 2 and 4. We assessed the interactive associations between physical activity and the <i>APOE</i> ε4 allele on the longitudinal changes in MoCA scores and striatal DAT activities.</p> <p><b>Results:</b> A total of 173 early PD patients (age 63.3±10.0 years; 27% <i>APOE</i> ε4 <span>carriers</span>) were included. The <i>APOE</i> ε4 allele showed a steeper rate of cognitive decline than the non-<i>APOE</i> ε4 allele (estimate -1.33; 95% CI, -2.12 to -0.47; <i>p</i>=0.002). However, there was a significant interaction between physical activity and <i>APOE</i> ε4, such that higher physical activity was related to slower <i>APOE</i> ε4-related cognitive decline (estimate 0.007; 95% CI, 0.003 to 0.011; <i>p</i>=0.001). No<span> significant interaction was found between physical activity and the <i>APOE</i> ε4 allele regarding the change in striatal DAT activities.</span></p> <p><span><span><b>Conclusion:</b> Increased physical activity attenuated <i>APOE</i> ε<span>4</span>-related vulnerability to early cognitive decline in PD patients. T<span>his protective effect did not appear to be mediated by striatal dopaminergic function.</span></span></span></p> <p><span><span><b>Classification of evidence</b>: This study provides Class II evidence that increased physical activity was associated with decreased <i>APOE</i> ε4-related early cognitive decline in PD patients.</span></span></p>
NYU -Machine Learning Data (coronal_pd_fs directory converted to BART file format)
<p>This is part of the training and test data that was used for the 2017 MRM manuscript on learning a variational network to reconstruct accelerated MR data (If you work with this data, please cite this paper):</p> <p>Hammernik K, Klatzer T, Kobler E, Recht M, Sodickson D, Pock T, Knoll F. Learning a Variational Network for Reconstruction of Accelerated MRI Data. Magnetic Resonance in Medicine 79: 3055–3071 (2018)</p> <p>The data has been converted to the BART cfl format. The same data is available in the MATLAB format on GLOBUS (https://app.globus.org/file-manager?origin_id=15c7de28-a76b-11e9-821c-02b7a92d8e58&origin_path=%2F). k-Space data is partly available in the ismrmrd file format at mridata.org.</p>
Data for "Transparent Josephson Junctions in Higher-Order Topological Insulator WTe2 via Pd Diffusion"
<p>Data for the publication "Transparent Josephson Junctions in Higher-Order Topological Insulator WTe<sub>2</sub> via Pd Diffusion".</p> <p>Updated version as accepted by Physical Review Materials. </p>
Mizagliflozin and Phloretin in experimental PD
<p><span>Here we tested a selective blocker of sodium glucose co-transporter 1, mizagliflozin, as well as phloretin, a non-selective blocker of facilitative glucose channels in an experimental model of peritoneal dialysis in anesthetized Sprague-Dawley rats.</span></p>
AMP PD Target Explorer Demo for MJFF Data Community
<p>This demo, provided by Victoria Dardov, Ha Duong, Barry Landin, and Dave Vismer of Technome, was hosted by the Michael J. Fox Foundation's Data Community of Practice (DCOP). For more information on the DCOP, please contact: researchcommunity@michaeljfox.org.</p> <p>During this recording, colleagues from Technome provided an overview from the recently released <a href="https://target-explorer.amp-pd.org/" target="_blank" rel="noopener">AMP® PD Target Explorer.</a> </p> <p>AMP® PD (the Accelerating Medicines Partnership Parkinson’s Disease) program is a partnership between FNIH, NINDS, NIA, FDA, Abbvie, GSK, Pfizer, Sanofi, BMS, Verily, ASAP and MJFF) generates and consolidates data from eight unified cohorts (BioFIND, HBS, LBD, LCC, PDBP, PPMI, STEADY-PD3 and SURE-PD3). Data was generated using standardized technology and centrally harmonized and quality controlled. All data was generated from samples collected under similar protocols. This data harmonization process and single data use policy facilitates and simplifies cross-cohort analysis. </p> <p>The AMP PD <a href="https://target-explorer.amp-pd.org/" target="_blank" rel="noopener">Target Explorer</a> is a public resource with open access for exploring nominated genes and proteins from AMP PD data that might be implicated in Parkinson's Disease. The Target Explorer integrates many AMP PD work streams focused on identifying new biomarkers and novel drug targets, with the goal of accelerating treatment discovery for patients with Parkinson's Disease.</p> <p>With the Target Explorer, researchers can explore targets from genomics, transcriptomics, and proteomics data, contributed by the AMP PD community. Use the Target Explorer to compare your findings with the findings of other researchers by entering your list of potential targets into the search engine to find out where they appear in other researchers’ analyses.</p> <p>Researchers can also <a href="https://target-explorer.amp-pd.org/become-a-submitter" target="_blank" rel="noopener">request to contribute</a> to the target lists and be featured in <a href="https://target-explorer.amp-pd.org/teams" target="_blank" rel="noopener">the teams and lists section.</a>. If you are interested in contributing findings from a recent publication or preprint, you can fill out the form in the <a href="https://target-explorer.amp-pd.org/become-a-submitter" target="_blank" rel="noopener">Become a Contributor</a> section.</p> <p>To access a streaming copy of this recording with a variable resolution, please <a href="https://share.vidyard.com/watch/2cGHZiPH1fieQWg9APUKaN" target="_blank" rel="noopener">visit this link</a>.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.